UK leads the world in rapid activation of complex early-phase ATiMP trial

The UK has demonstrated the strength of its ongoing clinical trial reforms by setting up a highly complex, early-phase advanced therapy trial in just 113 days. The Newcastle Advanced Therapy Treatment Centre is the first site in the world to activate the ‘CHILL’ study (sponsored by Quell Therapeutics).

The trial pioneers the use of advanced cell therapies (CAR-Tregs) for severe autoimmune conditions like rheumatoid arthritis, successfully pivoting the technology away from its traditional use in cancer.